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Abstract
A 43-year-old African American with end-stage renal dis-
ease (ESRD) associatedwithmembranous nephropathy and
a previously failed renal transplant had received cinacalcet
to treat his secondary hyperparathyroidism. Serum calcium
and phosphorus levels remained within normal limits, and
serum parathyroid levels had dropped significantly follow-
ing treatment initiation. However, within 7 months, the pa-
tient experienced extensive necrotic bilateral medial thigh
ulcers. These were biopsied and found to be a result of cal-
ciphylaxis. The patient ultimately required an urgent subto-
tal parathyroidectomy and recovered well with completely
healed ulcers.
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The case
The patient was a 43-year-old obeseAfricanAmericanmale
with a past medical history significant for end-stage renal
disease (ESRD) secondary to membranous nephropathy
and pulmonary embolism requiring anticoagulation with
warfarin. He underwent a cadaveric renal transplantation
that had failed because of non-reversible ATN in the setting
of hypotension from cytokine release syndrome while tak-
ing thymoglobulin. Shortly after transplant failure, the pa-
tient re-initiated haemodialysis and was started on cinacal-
cet 30 mg orally per day (Table 1). At that time, the patient
had normal serum calcium in the presence of highly ele-
vated parathyroid hormone (PTH) levels (max: 2516 pg/
mL). His Ca × PO4 product was elevated (68) at the ini-
tiation of treatment. As per outpatient pharmacy records,
the patient’s prescriptions were filled regularly, and he con-
firmed that he was taking his medications as prescribed.
During the 7 months, following the initiation of cinacal-
cet, the patient was seen closely in the outpatient setting
and denied any weakness, fatigue, constipation, nausea or
abdominal pain. In the following months, the patient’s cal-
cium level remained within normal limits, and his PTH
serum level dropped to 361 pg/mL. As such, the determi-
nation was made that cinacalcet treatment in this patient
was effective, and the patient continued on this regimen.
Eight months after initiation of cinacalcet, the patient
complained of superficial ulcerations on his inner thighs bi-
laterally (Figure 1a). A biopsy was performed and revealed
epidermal necrosis and ulceration with a dermal acute in-
flammatory infiltrate. No histologic evidence of calciphy-
laxiswas seen, and vonKossa stainwas negative for calcium
at that time. Despite normal serum calcium levels, the pa-
tientwas titrated up on his cinacalcet dose from30mgorally
daily to 60 mg orally twice daily after identification of the
ulcers; PTHat this timewas 361.5 pg/mL, and theCa×PO4
product had increased to 75. The lesions developed rapidly
over the following weeks to several large eschars over the
inner aspect of his thighs with increasing pain. The eschar
on his left inner thigh began draining significant amounts
of clear fluid, saturating his dressing. Empiric antibiotics
(ciprofloxacin and metronidazole) were begun prior to the
return of wound culture data that ultimately revealed a sig-
nificant growth of staphylococcus aureus. It was noted that
the previously tender brown papules had progressed to ar-
eas of sclerotic and ulcerated plaques with a black necrotic
base. Two weeks after this initial evaluation as an outpa-
tient, the patient was admitted with an elevated white count
and low-grade fevers concerning for infection. The patient
was started on intravenous vancomycin, ceftazidime and
metronidazole for broad spectrum coverage. The ulcer was
cultured and confirmed the growth of coagulase negative
S. aureus, which was suggestive of skin flora. A subse-
quent biopsy of the necrotic lesions revealed microcalcific
deposits in the walls of small subcutaneous vessels associ-
ated with extensive intraluminal thrombosis (Figure 2a and
b). The larger deep dermal vessels demonstrated promi-
nent calciumdeposits and obliterative intraluminal thrombi.
The subcutis, dermis and epidermis exhibited changes
of ischaemic infarction. Of note, at the time of biopsy-
proven calciphylaxis, the patient’s PTH was 394.2 pg/
mL with a serum calcium of 9.0 mg/dL.
C© The Author 2009. Published by Oxford University Press [on behalf of ERA-EDTA]. All rights reserved.
For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Cinacalcet refractory calciphylaxis 69
Table 1. Results of patient laboratory investigations before and after treatment with cinacalcet
Initiation of Development Prior to Four months
treatment of ulcerations surgery Recovery post-surgery
PTH 361.5 361.5 394.2 <Assay range 4.2
Calcium 8.5 8.7 7.9 8.6 6.3
HCO3− 25 24 28 25 25
Phosphorus 8 8.6 5.6 3.5 4.4
Magnesium 2.1 2.3 2.3 2.1 1.4
Albumin 3.1 3.3 3.3 2.8 3.8
Na 137 136 136 142 143
K 5.2 3.9 4.6 4.1 4.4
Cl 96 93 93 99 103
BUN 68 43 48 35 71
Cr 18.06 12.29 10.03 5.54 6.72
Glucose 76 75 84 98 185
Ca × PO4 product 68 74.8 44 30.1 27.7
Fig. 1. (a) Proximal calciphylaxis: bilateral inner thighs (while on cinacalcet). (b) Resolving calciphylaxis: 8 weeks after stopping cinacalcet and
following sub-total parathyroidectomy.
Fig. 2. (a) Tissue biopsy of calciphylaxis highlighting calciumphosphate deposition (×10magnification). (b) Tissue biopsy of calciphylaxis highlighting
calcium phosphate deposition (×40 magnification).
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IV antibiotic treatment was continued and the patient un-
derwent an urgent and uneventful subtotal parathyroidec-
tomy. Histological evaluation of the parathyroid glands
showed hyperplasia. Cinacalcet treatment was discontin-
ued and the thigh lesions continued to improve over the
next 8 months following subtotal parathyroidectomy with
conservative wound therapy (Figure 1b). His PTH, serum
calcium and phosphate returned to normal levels.
Discussion
Calciphylaxis, or calcific uraemic arteriolopathy, is a rare
disorder of vascular calcification that primarily affects pa-
tientswith a history of end-stage renal disease, including pa-
tients who have undergone renal transplantation [1]. While
the pathogenesis of the disorder is not fully elucidated, the
likely mechanism is small blood vessel occlusion and lo-
cal ischaemia resulting in infarction of the involved tissues,
which is responsible for the characteristic skin ulcerations
[2]. There are several predisposing factors associated with
this condition including renal failure, uraemia, diabetes
mellitus, warfarin use, obesity, hyperparathyroidism, and
elevated calcium–phosphate product [2]. It is likely that
these conditions disrupt calcium homeostasis and favour
the precipitation and deposition of calcium in small blood
vessels leading to the disorder; however, no single risk fac-
tor is necessary or sufficient to produce the clinical features
of calciphylaxis [3,4].
Therapeutic options for calciphylaxis are limited and
clearly unsatisfactory given the continued high mortality
of the disease. The mainstay of therapy includes preven-
tion with calcium and phosphate control in patients at risk,
avoidance of skin trauma and local wound care when ulcer-
ations develop [5]. In addition to local wound care, medical
therapy with sodium thiosulfate has been reported with suc-
cess [6,7], and Vassa et al. have used hyperbaric oxygen in
the treatment of calciphylaxis ulcers [8,9]. More recently,
calcimimetics have been used in the treatment of calci-
phylaxis. Cinacalcet, a type II calcimimetic, increases the
sensitivity of parathyroid cells to extracellular calcium and
thereby reduces the secretion of PTH. In 2004, the US Food
and Drug Administration (FDA) approved cinacalcet-HCl
(Sensipar R©, Amgen) for the treatment of secondary hyper-
parathyroidism in patients with chronic kidney disease on
dialysis. The drug was also approved for the treatment of
hypercalcaemia in patients with a parathyroid carcinoma at
the recommended oral starting dose of 30 mg once daily.
Cinacalcet has also been suggested as an alternative treat-
ment for patients with primary or secondary hyper parathy-
roidism who do not meet the criteria for parathyroidectomy
or in whom parathyroidectomy has failed [10,11].
Experience with calcimimetics in the treatment of calci-
phylaxis is sparse and limited to a few case reports. Velasco
et al. reported a case of distal calciphylaxis successfully
treated with cinacalcet as an alternative to parathyroidec-
tomy [12]. In his report, treatment with cinacalcet 60–
120 mg/day for a period of 9 months reduced PTH lev-
els with resolution of the distal leg ulcers. In our patient,
however, cinacalcet reduced PTH values significantly and
normalized serum calcium levels but failed to produce a
clinical response. He was on cinacalcet for 8 months prior
to the development of the thigh ulcers. After identification
of the ulcers, our patient’s cinacalcet dose was uptitrated to
60 mg orally twice daily for a period of 4 weeks; however,
the thigh ulcers did not improve. Sub-total parathyroidec-
tomy has been used in cases of refractory calciphylaxis,
which was required in our patient and resulted in a dra-
matic clinical improvement in his thigh ulcers over time
(Figure 1b).
In summary, our patient demonstrated a case of clinical
resistance to cinacalcet for the pharmaceutical treatment
of proximal bilateral calciphylaxis in the setting of sec-
ondary hyperparathyroidism secondary to renal failure. He
had several predisposing factors to the development of this
condition including ESRD, obesity, high Ca× PO4 product
and warfarin use. Despite a significant decrease in PTH,
discontinuation of warfarin, and continued cinacalcet ther-
apy, he progressed to calciphylaxis ulcerations and required
a subtotal parathyroidectomy. This case underscores the im-
portance of prevention of calciphylaxis in patients who are
at risk for the condition and the potential fallibility of cal-
cimimetics in the treatment of calciphylaxis for patients
with secondary hyperparathyroidism.
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